All News

The newly approved prefilled syringe version of Shingrix is expected to simplify administration and supports efforts to increase adult vaccination against shingles (herpes zoster).

Priority review was based on results from the Phase IIb SunRISe-1 trial, which showed that patients treated with TAR-200 for high-risk non-muscle invasive bladder cancer showed a complete response rate of 82.4%.

The reality TV star and certified obesity physician Dr. Holly Lofton plan to use the show to further educate GLP-1 users on potential side effects.

Research from a recent Cadent study reveals the growing impact of TV and connected TV advertising in raising medication awareness across diverse demographic groups, highlighting shifting dynamics in how patients discover treatment options.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, explains how E7386 and lenvatinib work together to target advanced endometrial carcinoma through dual mechanisms of action and WNT pathway modulation.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating unresectable hepatocellular carcinoma.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.

Leqselvi are currently available 8 mg tablets for severe Alopecia Areata treatments in adult patients.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of unresectable hepatocellular carcinoma.

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

LEO Pharma expected to expand Spevigo developments as well as improve access to care.

Chandler previously held leadership positions at Cencora and CVS Health.

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant and clinically meaningful reductions in cardiovascular events across a broad range of patients with heart failure.

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed that the doravirine/islatravir combination was non-inferior to both baseline antiretroviral therapy and to bictegravir/emtricitabine/tenofovir alafenamide in treating HIV.

The majority of respondents not already enrolled in the program have concerns that the program won’t survive until the point when they need it.

Bravecto Quantum becomes first FDA approved drug to protect dogs against fleas and ticks for 8 to 12 months.

rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of clogged arteries and heart disease in women.

Gala will succeed Bruce Cozadd, effective August 11, 2025.

The company will continue to experiment with microgravity-derived experiments.

The agency stated that the letters were made public to promote transparency.

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

The new doll will include an insulin pump, a glucose monitor, and a dress featuring international symbols for diabetes awareness.

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable efficacy in amyloid plaque and P-tau217 reduction while lowering the risk of amyloid-related imaging abnormalities with edema or effusion in patients with early Alzheimer disease.

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

The drug is currently in Phase 1 clinical trials for gastric cancer treatments.

Ohtuvayre will become part of Merck’s cardio-pulmonary pipeline.

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres for unresectable hepatocellular carcinoma.